ReviewAdvances in experimental medicine and biology2026
Supramolecular Assemblies Drive Activation of Inflammasomes.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammasomes are large cytosolic protein complexes that detect and respond to pathogenic and endogenous danger signals, triggering critical innate immune defenses. This chapter outlines the structural and mechanistic features of canonical inflammasomes, focusing on NLRP1, NLRP3, NAIP-NLRC4, NLRP6, and AIM2. Canonical inflammasomes often comprise a sensor protein (e.g., an NLR or AIM2), the adaptor ASC, and pro-caspase-1, which are assembled upon ligand binding. NLR sensors detect diverse signals, ranging from bacterial toxins and lipopolysaccharides to crystals and ATP, while AIM2 recognizes cytosolic double-stranded DNA. Once activated, these inflammasomes facilitate caspase-1-dependent maturation of IL-1β and IL-18, as well as cleavage of gasdermin D, culminating in pyroptotic cell death and pro-inflammatory cytokine release. Structural insights reveal that inflammasome activation transitions from an autoinhibited state to filamentous or ring-shaped supramolecular assemblies. Despite ligand diversity and varying activation pathways, inflammasomes share unifying principles in their oligomerization-driven activation. Elucidating these mechanisms advances our understanding of how cells mount rapid, robust immune responses and paves the way for developing therapeutic interventions in inflammatory and infectious diseases.
Indexed as
Identifiers
42334537What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.